Front Row Advisors LLC Halozyme Therapeutics, Inc. Transaction History

Front Row Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$37.81 - $52.4 $756 - $1,048	-20 Reduced 12.58%	139 $7,000
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $5,355 - $6,670	159 New	159 $6,000
Q1 2023 May 22, 2023	BUY	$32.86 - $55.7 $4,238 - $7,185	129 Added 2580.0%	134 $5,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $3,121 - $5,291	-95 Reduced 95.0%	5 $13,000
Q4 2022 Feb 15, 2023	BUY	$40.06 - $59.44 $761 - $1,129	19 Added 23.46%	100 $6,000
Q3 2022 Nov 15, 2022	BUY	$38.53 - $51.78 $3,120 - $4,194	81 New	81 $3,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.